SPRO
Spero Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Spero Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Spero Therapeutics, Inc.
1.07
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | GlaxosmithklineGlaxosmithkline | $20.3M | 42.37% | 0.00% | |
| 2 | PfizerPfizer | $5.3M | 11.14% | 0.00% | |
| 3 | Vanguard Capital ManagementVanguardindex-like | $4.5M | 9.39% | +13.13% | |
| 4 | Renaissance TechnologiesRenaissance Technologies | $2.1M | 4.37% | −20.29% | |
| 5 | AlphabetAlphabet | $2.0M | 4.10% | 0.00% | |
| 6 | Susquehanna International GroupSusquehanna International | $1.8M | 3.72% | +111.62% | |
| 7 | BlackRockBlackRockindex-like | $1.3M | 2.74% | +37.21% | |
| 8 | Geode Capital ManagementGeodeindex-like | $1.3M | 2.61% | +8.93% | |
| 9 | Raymond James FinancialRaymond James Financial | $1.2M | 2.41% | new | |
| 10 | Two Sigma InvestmentsTwo Sigma | $846,019 | 1.77% | −56.77% | |
| 11 | Arrowstreet Capital, Limited PartnershipArrowstreet Capital, Limited Partnership | $735,864 | 1.54% | new | |
| 12 | Vanguard Fiduciary TrustVanguard Fiduciary Trustindex-like | $635,702 | 1.33% | +8.91% | |
| 13 | GSA Capital PartnersGSA Capital Partners | $632,000 | 1.32% | +2.73% | |
| 14 | Dimensional Fund AdvisorsDimensional | $607,616 | 1.27% | +823.21% | |
| 15 | Goldman Sachs GroupGoldman Sachs | $567,937 | 1.18% | new | |
| 16 | Jane Street GroupJane Street | $512,713 | 1.07% | +27.02% | |
| 17 | State StreetState Streetindex-like | $474,600 | 0.99% | 0.00% | |
| 18 | UBS GroupUBS | $308,693 | 0.64% | +4542.07% | |
| 19 | Bridgeway Capital ManagementBridgeway | $253,708 | 0.53% | 0.00% | |
| 20 | Northern TrustNorthern Trustindex-like | $239,286 | 0.50% | −10.51% | |
| 21 | Point72 Asset ManagementPoint72 | $230,673 | 0.48% | +74.93% | |
| 22 | Ionic Capital ManagementIonic | $226,963 | 0.47% | −47.59% | |
| 23 | Federation des caisses Desjardins du QuebecFederation des caisses Desjardins du Quebec | $202,180 | 0.42% | new | |
| 24 | Shay CapitalShay Capital | $159,984 | 0.33% | +2.90% | |
| 25 | Citadel AdvisorsCitadel | $144,976 | 0.30% | −84.59% |
60 managers report $47.9M of Spero Therapeutics on form 13F for the quarter ended Jun 30 '26. 8 of them hold 80% of it; Glaxosmithkline is largest at 42.37%.
Linked news
Expected move
No implied move.
No implied move.
No implied move.